Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
| Revenue (TTM) | $2.38B |
| Gross Profit (TTM) | $2.29B |
| EBITDA | $985.84M |
| Operating Margin | 41.10% |
| Return on Equity | 41.00% |
| Return on Assets | 22.00% |
| Revenue/Share (TTM) | $8.91 |
| Book Value | $7.63 |
| Price-to-Book | 7.25 |
| Price-to-Sales (TTM) | 5.98 |
| EV/Revenue | 5.65 |
| EV/EBITDA | 13.61 |
| Quarterly Earnings Growth (YoY) | 43.60% |
| Quarterly Revenue Growth (YoY) | 10.00% |
| Shares Outstanding | $251.35M |
| Float | $204.46M |
| % Insiders | 1.82% |
| % Institutions | 106.64% |
Volatility is currently contracting
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company's website. To access the conference call, please dial (800) 715-9871 (domes.
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EXEL and any ticker you trade — then tracks every position and per-strategy win rate.
